Lumina Fund Management Llc decreased its stake in Regeneron Pharmaceuticals (REGN) by 50.94% based on its latest 2017Q4 regulatory filing with the SEC. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company's stock worth $138,000 after purchasing an additional 307 shares during the period.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide.The firm is valued at $34.56 billion. The stock decreased 1.08% or $3.52 during the last trading session, reaching $321.56. 846,108 shares of the company traded hands, compared to its average volume of 792,429. It has underperformed by 25.74% the S&P500.
Investors sentiment decreased to 0.9 in 2017 Q4. Its up 0.14, from 0.88 in 2017Q3. Funds hold 69.17 million shares thus 6.15% less from 2017Q3's 73.70 million shares. 36 funds opened positions while 60 raised stakes. Orbimed Advsr Ltd Co accumulated 854,600 shares.
In other news, major shareholder Sanofi bought 87,298 shares of the firm's stock in a transaction that occurred on Wednesday, January 11th. Peddock Limited Liability Corp invested in 0.01% or 55 shares. Meritage Portfolio has 259,980 shares.
Several large investors have recently bought and sold shares of REGN. Alpine Woods Cap Ltd Liability owns 3,000 shares for 0.06% of their portfolio. Teacher Retirement Systems Of Texas owns 37,721 shares for 0.09% of their portfolio. Checchi Advisers Ltd Liability Corp reported 641 shs.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.71% during mid-day trading on Wednesday, hitting $397.80. American Century holds 877,587 shares or 0.33% of its portfolio. (NASDAQ:REGN) or 6,027 shares. First Interstate Fincl Bank reported 140,990 shares. Three research analysts have rated the stock with a sell rating, eighteen have given a hold rating and eight have assigned a buy rating to the company's stock. Therefore 32% are positive. Regeneron Pharmaceuticals Inc. had 121 analyst reports since July 28, 2015 according to SRatingsIntel. SunTrust maintained the shares of REGN in report on Thursday, November 9 with "Hold" rating. Barclays Capital maintained the stock with "Overweight" rating in Wednesday, January 24 report. On Sunday, February 11 the rating was maintained by Piper Jaffray with "Buy". (NASDAQ:REGN) rating. Jefferies has "Hold" rating and $421.0 target. The company has a consensus rating of "Hold" and a consensus price target of $449.49. The firm earned "Hold" rating on Monday, November 27 by BMO Capital Markets. On Thursday, November 9 the stock rating was maintained by Morgan Stanley with "Equal-Weight". Finally, Leerink Swann lowered their price objective on shares of Regeneron from $568.00 to $502.00 and set an "outperform" rating for the company in a research report on Friday, February 9th. (NYSE:VZ), 10 have Buy rating, 0 Sell and 19 Hold. BMO Capital Markets raised their price objective on shares of Regeneron from $398.00 to $444.00 and gave the company a "market perform" rating in a research report on Thursday, February 8th.
Analysts await Microsoft Corporation (NASDAQ:MSFT) to report earnings on April, 26. Griffin Asset accumulated 3,441 shares or 0.23% of the stock. After $4.46 EPS report last quarter, Wall Street now predicts 13.90 % EPS growth of Regeneron Pharmaceuticals, Inc. This's net activity of $1.71 million. Pinebridge Ltd Partnership reported 0.45% stake.
Since February 9, 2018, it had 0 insider buys, and 3 sales for $1.71 million activity.
Telemus Capital Llc, which manages about $2.42 billion and $1.29B US Long portfolio, upped its stake in Vanguard Intl Equity Index F (VWO) by 13,600 shares to 29,852 shares, valued at $1.37M in 2017Q4, according to the filing. It also reduced its holding in Juniper Networks Inc Com (NYSE:JNPR) by 13,246 shares in the quarter, leaving it with 185,807 shares, and cut its stake in Cvs Health Corp Com (NYSE:CVS).
Among 33 analysts covering Regeneron Pharmaceuticals Inc. Last quarter $4.46 earnings per share was reported. They expect $1.12 earnings per share, up 17.89% or $0.17 from last year's $0.95 per share. REGN's profit will be $546.58 million for 15.82 P/E if the $5.08 EPS becomes a reality. Robert W. Baird reissued a "positive" rating and set a $379.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, December 12th.
Big Money Sentiment is 1.17 in 2017 Q4. The ratio has no change due to REGN positioning: 62 sold and 161 reduced. only 71 funds amassed positions and 191 increased positions. 3,270 were accumulated by Dearborn Prns. State Of Tennessee Treasury Department reported 22,694 shares. Sg Americas Ltd Liability Company has invested 0.04% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 9,000 shares. On Thursday, November 9 the stock of Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 14.19% since April 16, 2017 and is downtrending.
Lagoda Investment Management Lp increased its stake in Regeneron Pharmaceuticals (REGN) by 15.54% based on its latest 2017Q4 regulatory filing with the SEC. 3,679 are owned by Meag Munich Ergo Kapitalanlagegesellschaft Mbh. Stratos Wealth Partners Limited holds 0% of its capital in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 4,365 shares. Solaris Asset Lc, a New York-based fund reported 125 shares. 248,001 were accumulated by Ameriprise Inc. (NASDAQ:PCLN). Thompson Siegel And Walmsley Limited Company reported 152 shares or 0% of all its holdings. Also, Director Joseph L. Goldstein sold 1,000 shares of the business's stock in a transaction dated Friday, February 9th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Analysts Issued Domtar Corp (UFS) Target Price at $40.40
In 2017Q4 Securities and Exchange filling is reported Qv Investors Inc's stake in Domtar Corp (UFS) which was reduced by 22.6%. A company that manages their assets well will have a high return, while if manages their assets poorly will have a low return.
New Drugs May Be Big Advance in Lung Cancer Care
Keytruda is also used to treat melanoma, Hodgkin lymphoma, and cancers of the stomach, head, neck and bladder. But the survival rate for patients that took Keytruda was dramatically higher: 69.2 percent.